Low Expectancy of Conversion Surgery with R0 Resection in Patients with CEA > 5.0 ng/mL at the Initial RECIST Evaluation for Metastatic Gastric Cancer.
chemotherapy
conversion surgery
metastatic gastric cancer
predictor
tumor marker
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
29 Oct 2023
29 Oct 2023
Historique:
received:
17
10
2023
accepted:
27
10
2023
medline:
14
11
2023
pubmed:
14
11
2023
entrez:
14
11
2023
Statut:
epublish
Résumé
This retrospective study examined early the predictive factors for successful conversion surgery (CS) with R0 resection in patients with metastatic gastric cancer (MGC) who underwent systemic chemotherapy. This study included 204 patients diagnosed with metastatic gastric adenocarcinoma, who received chemotherapy between 2009 and 2019. Of these patients, 31 (15%) underwent CS with R0 resection. The incidence of CS with R0 resection was not affected by the volume of metastatic lesions or the presence of peritoneal metastasis. The overall survival time of the CS with R0 resection group was significantly longer than that of the non-CS group (hazard ratio, 0.12; 95% confidence interval, 0.07-0.23;
Identifiants
pubmed: 37958371
pii: cancers15215197
doi: 10.3390/cancers15215197
pmc: PMC10650046
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Lancet. 2010 Aug 28;376(9742):687-97
pubmed: 20728210
Gastric Cancer. 2021 Jan;24(1):1-21
pubmed: 32060757
World J Gastrointest Oncol. 2019 Jan 15;11(1):17-27
pubmed: 30984347
Pancreatology. 2020 Jul;20(5):919-928
pubmed: 32563596
Ann Oncol. 2017 Nov 01;28(11):2786-2792
pubmed: 28945895
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
Ann Oncol. 2019 Jan 1;30(1):19-33
pubmed: 30475956
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
World J Gastroenterol. 2019 Jun 14;25(22):2743-2751
pubmed: 31235997
Lancet Oncol. 2016 Mar;17(3):309-318
pubmed: 26822397
Ann Surg. 2019 Apr;269(4):733-740
pubmed: 29227344
Eur J Surg Oncol. 2021 May;47(5):1005-1011
pubmed: 33189492
Ann Surg Oncol. 2015 Oct;22(11):3618-24
pubmed: 25663597
Oncol Lett. 2010 Jul;1(4):743-747
pubmed: 22966373
Gastric Cancer. 2019 Nov;22(6):1285-1293
pubmed: 31065878
J Gastrointest Surg. 2016 Jul;20(7):1331-42
pubmed: 27114246
J Cancer Res Clin Oncol. 2021 Aug;147(8):2385-2396
pubmed: 33534051
Lancet Gastroenterol Hepatol. 2019 Jul;4(7):501-510
pubmed: 31101534
Cancer Med. 2019 Sep;8(11):5194-5201
pubmed: 31353821
Ann Surg. 2009 Aug;250(2):187-96
pubmed: 19638912
Int J Surg. 2018 May;53:360-365
pubmed: 29654967
Gastric Cancer. 2016 Apr;19(2):329-338
pubmed: 26643880
Lancet Oncol. 2022 Feb;23(2):234-247
pubmed: 35030335
Gastric Cancer. 2018 Mar;21(2):315-323
pubmed: 28616743
Ann Gastroenterol Surg. 2021 Oct 20;6(2):227-240
pubmed: 35261948
Ann Surg Oncol. 2019 Dec;26(13):4452-4463
pubmed: 31529308
Gastric Cancer. 1998 Dec;1(1):10-24
pubmed: 11957040
Gastric Cancer. 2019 Nov;22(6):1215-1225
pubmed: 30955110
Lancet. 2021 Jul 3;398(10294):27-40
pubmed: 34102137
Gastric Cancer. 2016 Jul;19(3):685-6
pubmed: 27055560